Completed PHASE4 INTERVENTIONAL NCT00254033

Apathy Associated With Alzheimer's Disease

The Role of the Dopaminergic Brain Reward System in Apathy Associated With Alzheimer's Disease

Sponsor: American Health Assistance Foundation

Interventions Dextroamphetamine Methylphenidate

Updated 5 times since 2017 Last updated: Apr 26, 2017 Started: Oct 31, 2003 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00254033, this PHASE4 trial focuses on Alzheimer Disease and Dementia and remains completed. Sponsored by American Health Assistance Foundation, it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

American Health Assistance Foundation
Sunnybrook Health Sciences Centre

Data source: Sunnybrook Health Sciences Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada